Beta2-adrenergic System and Training

Trainability of the beta2-adrenergic System With Respect to Performance

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04616261

Enrollment

Registered

2020-11-04

Start date

2020-11-10

Completion date

2022-11-10

Last updated

2020-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This project aims to examine the trainability of the beta2-adrenergic system with respect to the individual performance response

Interventions

BEHAVIORALTraining

6 weeks of training

DRUGFormoterol

inhalation of 54 microg formoterol

DRUGPlacebo

inhalation of placebo

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* 18 to 45 years of age * Trained individuals with a maximal oxygen uptake above 55 ml/min/kg * Body mass index lower than 26

Exclusion criteria

* Allergy towards study drug * Unacceptable side effects to the study drug * Chronic disease deemed by the MD to interfere with the study * Smoking * Use of prescription medicine

Design outcomes

Primary

Measure	Time frame	Description
Sprint performance	½ hour after administration of formoterol or placebo	Change in power output during maximal cycling in response to formoterol

Secondary

Measure	Time frame	Description
Cycling endurance performance	½ hour after administration of formoterol or placebo	Change in 4-min time trial performance in response to formoterol

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026